Hospitals Sue Eli Lilly Over 340B Claims Policy

Tampa General and Mary Hitchcock hospitals challenge Eli Lilly's mandate for 340B drug claims data submission.

Updated on Oct. 20, 2026 in Healthcare

Isometric editorial illustration of a metallic container balanced on an architectural pedestal, representing the tension of pharmaceutical pricing regulations. — Tampa General and Mary Hitchcock hospitals have filed lawsuits against Eli Lilly, challenging the company's mandatory drug claims data reporting policy. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies be allowed to condition drug discounts on the submission of internal claims data?

Two hospitals have filed lawsuits against Eli Lilly and Lilly USA regarding a policy requiring covered entities to submit in-house claims data to maintain 340B pricing. The legal action follows Lilly's decision to instruct wholesalers to end discounts for facilities that failed to comply with the data demands by the established deadline.

Why it matters

The dispute centers on Eli Lilly's effort to curb potential fraud, waste, and abuse within the 340B program by mandating greater transparency. Hospitals argue the policy places an undue burden on providers and significantly inflates the costs of essential medications.

Eli Lilly reported that 2,350 organizations, or approximately 70% of covered entities, have submitted data to maintain access to 340B pricing. Meanwhile, the price of Mounjaro at Tampa General Hospital rose 35.9%, from $750.52 to $1,019.74 per unit.

The players

Eli Lilly

This global pharmaceutical company is a major manufacturer of insulin and other diabetes medications.

Tampa General Hospital

Located in Florida, this academic medical center serves as a primary teaching hospital for the region.

Mary Hitchcock Memorial Hospital

This medical center based in Lebanon, New Hampshire, is a flagship teaching hospital for the Dartmouth Health system.

American Hospital Association

This national organization represents thousands of hospitals and health systems across the United States.

Washington Legal Foundation

This nonprofit public interest law firm focuses on defending free enterprise and individual liberty in the legal system.

The details

Lilly implemented the requirement in February 2026, giving hospitals five business days to provide claims data or face the suspension of discounted pricing. Tampa General Hospital and Mary Hitchcock Memorial Hospital are both challenging these mandates in federal court, while receiving conflicting support from various industry organizations through amicus briefs.

February 2026: Lilly initiated its 340B data demands for hospitals.
June 1, 2026: Lilly issued a formal letter regarding the 340B data policy.
June 18, 2026: McKesson terminated 340B discounts for Tampa General Hospital.
July 2, 2026: Tampa General Hospital filed its lawsuit against Eli Lilly and Lilly USA.
September 22, 2026: The Washington Legal Foundation submitted an amicus brief.

Market Landscape

The litigation over pharmaceutical pricing requirements marks a contentious chapter in the oversight of the 340B Drug Pricing Program. Manufacturers are increasingly pushing for claims data to curb perceived waste, placing them in direct conflict with hospital systems that rely on 340B savings.

Patients may face higher out-of-pocket costs for essential medications like Mounjaro as hospital systems navigate the loss of 340B discounts. These price increases could potentially affect the affordability of care for individuals relying on these clinics for specialized drug treatments.

The takeaway

The tension between pharmaceutical manufacturers and healthcare providers underscores a growing struggle over transparency and pricing in the US drug market. Patients should monitor their local pharmacy costs closely, as disputes involving the 340B program often lead to sudden changes in pricing structures.